Regulation - Roche

Filter

Current filters:

Roche

Popular Filters

101 to 125 of 134 results

New Zealand agrees to fund Iressa but amends Tarceva use

05-07-2012

New Zealand's pharmaceutical management agency PHARMAC has approved the proposal to fund AstraZeneca's…

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

EMA investigating deficiencies in Roche's drug safety reporting

22-06-2012

The European Medicines Agency revealed yesterday that it is working with national medicines agencies…

EuropePharmaceuticalRegulationRoche

UK's NICE denies NHS access to Roche melanoma drug Zelboraf

15-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued draft guidance…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

Fake Avastin reignites "Track-and-Trace" debate, but the clock is ticking

14-06-2012

The US Food and Drug Administration announced in February that counterfeit vials of Roche/Genentech's…

AvastinLegalNorth AmericaPharmaceuticalRegulationRoche

FDA backs Roche's personalized breast cancer therapy Perjeta

11-06-2012

The US Food and Drug Administration on Friday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech's…

BiotechnologyGenentechNorth AmericaOncologyPerjetapertuzumabPharmaceuticalRegulationRoche

NZ's PHARMAC consults on funding for Iressa and Tarceva

31-05-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to:

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

EMA confirms Roche's MabThera made at Vacaville site poses no health risk

28-05-2012

Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines…

Anti-Arthritics/RheumaticsBiotechnologyMabTheraOncologyPharmaceuticalRegulationRoche

NICE recommends Roche's Tarceva for NSCLC

10-05-2012

Having received further previously requested data from Swiss drug major Roche (ROG: SIX), the UK drugs…

EuropePharmaceuticalPricingRegulationRocheTarceva

NICE turns down Roche breast cancer drug Avastin, citing too many uncertainties

18-04-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE), said this morning…

AvastinEuropeOncologyPharmaceuticalPricingRegulationRoche

SHA to fund Roche breast cancer drug Avastin in London

12-04-2012

Women with aggressive metastatic breast cancer in the UK capital London now have access to a drug which…

AvastinOncologyPharmaceuticalPricingRegulationRoche

Roche to file for trastuzumab emtansine this year, on positive Ph III results

03-04-2012

Swiss drug major Roche (ROG: SIX) says that top-line results of EMILIA, the first randomized Phase III…

BiotechnologyGenentechGlaxoSmithKlineOncologyPharmaceuticalRegulationResearchRochetrastuzumab

FDA approves first generics of Roche osteo drug Boniva

20-03-2012

The US Food and Drug Administration yesterday approved the first generic versions of Boniva (ibandronate)…

Anti-Arthritics/RheumaticsApotexBonivaGenericsMylan LaboratoriesNorth AmericaOrchid HealthcareRegulationRoche

NICE backs Roche RoActemra, but with PAS discount

22-02-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today recommended…

Anti-Arthritics/RheumaticsEuropePharmaceuticalPricingRegulationRoActemraRoche

European approval for Roche skin cancer drug Zelboraf

21-02-2012

Swiss drug major Roche (ROG: SIX) says that the European Commission has approved Zelboraf (vemurafenib)…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

UK NICE asks for more data on Tarceva, and Botox for migraine

17-02-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) today issued new draft…

AllerganBotoxEuropeNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarceva

Counterfeit Avastin found in USA by FDA

16-02-2012

The US Food and Drug Administration said yesterday that it is warning health care professionals and patients…

AvastinGenentechMarkets & MarketingNorth AmericaOncologyPharmaceuticalRegulationRoche

NICE views breast cancer drugs from GSK and Roche too expensive

14-02-2012

The UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

EuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRegulationRocheTyverb

Faster-than-expected FDA approval of Roche’s vismodegib

31-01-2012

There was good news for Swiss drug major Roche's (ROG: SIX)subsidiary Genentech yesterday, when it received…

BiotechnologyCurisErivedgeGenentechNorth AmericaOncologyPharmaceuticalRegulationRochevismodegib

EMA recommends approval of Roche’s Zelboraf

19-12-2011

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

Mixed NICE views on Faslodex and RoActemra

14-12-2011

There was mixed news this morning from the UK’s National Institute for Health and Clinical Excellence…

Anti-Arthritics/RheumaticsAstraZenecaEuropeFaslodexOncologyPharmaceuticalPricingRegulationRoActemraRoche

101 to 125 of 134 results

Back to top